-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$15.2529.79% Upside
Amicus Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover Amicus Therapeutics, Inc.?
Amicus Therapeutics, Inc. has been rated by research analysts at Bank of America Securities, Guggenheim, Morgan Stanley, Goldman Sachs in the past 90 days.